Stage IV Bladder Cancer Clinical Trial
Official title:
A Phase II Study of VEGF Trap (NSC 724770) in Patients With Recurrent or Metastatic Transitional Carcinoma of the Urothelium
This phase II trial is studying the side effects and how well VEGF Trap works in treating patients with recurrent, locally advanced, or metastatic cancer of the urothelium. VEGF Trap may stop the growth of tumor cells by blocking blood flow to the tumor.
Status | Completed |
Enrollment | 22 |
Est. completion date | April 2014 |
Est. primary completion date | April 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically confirmed transitional cell carcinoma (TCC) of the urothelium - Must have predominance of transitional histology, but foci of squamous and/or adenocarcinoma histology allowed - Poorly differentiated transitional cell carcinoma allowed - TCC of any of the following sites allowed: - Bladder - Renal pelvis - Ureter - Urethra - Measurable disease, defined as >= 1 unidimensionally measurable lesion >= 20 mm by conventional techniques OR >= 10 mm by spiral CT scan - Locoregionally advanced or metastatic disease that is not amenable to curative surgery and/or radiotherapy - Must have received 1 prior systemic chemotherapy regimen containing a platinum compound (e.g., cisplatin, carboplatin, or oxaliplatin) in the neoadjuvant, adjuvant, or metastatic setting - No evidence of CNS disease, including primary brain tumor or brain metastases - ECOG performance status 0-2 - Absolute neutrophil count >= 1,000/mm^3 - Platelet count >= 75,000/mm^3 - Bilirubin =< 1.5 times upper limit of normal (ULN) - AST or ALT =< 2.5 times ULN - Creatinine =< 2.5 times ULN OR creatinine clearance => 40 mL/min - Urine protein: creatinine ratio =< 1 OR 24-hour urine protein < 500 mg - INR =< 1.5 (unless on full-dose warfarin) - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for >= 6 months after completion of study treatment - No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies - No history of allergic reactions attributed to compounds of similar chemical or biological composition to other agents used in the study - No serious or nonhealing wound, ulcer, or bone fracture - No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days - No significant traumatic injury within the past 28 days - No clinically significant cardiovascular disease, including any of the following: - Myocardial infarction, coronary artery bypass graft, or unstable angina pectoris within the past 6 months - New York Heart Association class III or IV congestive heart failure - Serious cardiac arrhythmia requiring medication - Clinically significant peripheral vascular disease within the past 6 months - Cerebrovascular accident within the past 6 months - Pulmonary embolism, deep vein thrombosis, or other thromboembolic event within the past 6 months - Uncontrolled hypertension, defined as blood pressure (BP) > 150/100 mm Hg or systolic BP > 180 mm Hg (if diastolic BP < 90 mm Hg) within the past 3 months - No evidence of bleeding diathesis or coagulopathy - No uncontrolled intercurrent illness, including, but not limited to, any of the following: - Ongoing or active infection - Psychiatric illness or social situation that would preclude study compliance - Recovered from prior therapy - Prior biologic or targeted therapies allowed - No more than 1 prior systemic chemotherapy regimen for metastatic disease - No prior antiangiogenic therapy primarily targeting the vascular endothelial growth factor pathway - At least 4 weeks since prior radiotherapy or systemic therapy (6 weeks for mitomycin C or nitrosoureas) - More than 28 days since prior major surgery or open biopsy - More than 7 days since prior core biopsy - No concurrent major surgery - Concurrent full-dose anticoagulants (e.g., warfarin) allowed provided all of the following criteria are met: - In-range INR (usually between 2 and 3) on a stable dose of oral anticoagulant or low molecular weight heparin - No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices) - No other concurrent investigational agents - No concurrent combination antiretroviral therapy for HIV-positive patients |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | City of Hope | Duarte | California |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Tumor Response Rate | Response rate (RR) and progression free survival (PFS) were assessed in a 2-stage accrual design (22+18). A maximum of 40 patients were to be accrued to rule out a null hypothesized RR of 4% and PFS of 3 months versus alternative of 15% RR and 5.4 months PFS (corresponding to 4 month PFS of 40% vs 60%) with a=0.12 and ß=0.19. If no more than 1 objective response (no more than 4.5%), and no more than 10 instances of 4-month PFS (no more than 45%), were observed among the initial 22 patients, the study would be terminated early and declared negative. Tumor response was evaluated by CT or MRI using RECIST v1.0 criteria. Responders were confirmed partial or complete responses to treatment. |
From the start of the treatment until disease progression or recurrence, assessed up to 4 years | No |
Primary | Progression-free Survival (PFS) | Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions PFS using the product-limit method of Kaplan and Meier. | From start of treatment to time of progression, assessed up to 4 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02122172 -
Afatinib in Advanced Refractory Urothelial Cancer
|
Phase 2 | |
Completed |
NCT03229278 -
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
|
Phase 1 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01938573 -
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT00112905 -
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
|
Phase 2 | |
Completed |
NCT00072150 -
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
|
Phase 2 | |
Terminated |
NCT00072137 -
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
|
Phase 1 | |
Completed |
NCT00028756 -
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
|
Phase 3 | |
Terminated |
NCT00003452 -
Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder
|
Phase 2 | |
Completed |
NCT00003167 -
Gene Therapy in Treating Patients With Advanced Bladder Cancer
|
Phase 1 | |
Completed |
NCT00005831 -
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer
|
Phase 2 | |
Completed |
NCT00021099 -
Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer
|
Phase 2 | |
Terminated |
NCT01382706 -
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
|
Phase 2 | |
Active, not recruiting |
NCT04267575 -
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
|
N/A | |
Terminated |
NCT01954173 -
Adjuvant Radiation for High Risk Bladder Cancer
|
N/A | |
Terminated |
NCT00004856 -
Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium
|
Phase 2 | |
Active, not recruiting |
NCT04670445 -
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
|
N/A | |
Terminated |
NCT01282333 -
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01828736 -
Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma
|
Phase 2 | |
Terminated |
NCT02316548 -
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
|
Phase 2 |